OmniAb, Inc.

NasdaqGM OABI

OmniAb, Inc. Price to Sales Ratio (P/S) on January 14, 2025: 18.91

OmniAb, Inc. Price to Sales Ratio (P/S) is 18.91 on January 14, 2025, a -11.53% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

OmniAb, Inc. 52-week high Price to Sales Ratio (P/S) is 30.54 on April 09, 2024, which is 61.47% above the current Price to Sales Ratio (P/S).
OmniAb, Inc. 52-week low Price to Sales Ratio (P/S) is 17.78 on March 22, 2024, which is -6.02% below the current Price to Sales Ratio (P/S).
OmniAb, Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 23.21.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NasdaqGM: OABI

OmniAb, Inc.

CEO	Mr. Matthew W. Foehr
IPO Date	Sept. 30, 2021
Location	United States
Headquarters	5980 Horton Street
Employees	106
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.

Key trends

Past 5 years